North America Antibody Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration (Intravenous, Subcutaneous, and Others), By Format, By Source, By End User, By Disease Areas, By Country and Growth Forecast, 2023 - 2030

North America Antibody Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration (Intravenous, Subcutaneous, and Others), By Format, By Source, By End User, By Disease Areas, By Country and Growth Forecast, 2023 - 2030


The North America Antibody Therapeutics Market would witness market growth of 13.7% CAGR during the forecast period (2023-2030).

The safety profile of antibody therapeutics represents a compelling factor in their adoption. The targeted nature of antibodies minimizes off-target effects and reduces the risk of adverse events. This attribute is especially crucial in chronic conditions or diseases that require long-term treatment, where maintaining a favorable safety profile is paramount to ensuring patient compliance and overall well-being. Antibody therapeutics align seamlessly with this ethos, allowing for the customization of therapies based on patient-specific factors. The ability to engineer antibodies for specific targets or patient populations enhancses treatment precision and response rates, contributing to the growing adoption of personalized therapeutic strategies.

Continuous advancements in antibody engineering and discovery technologies contribute to the expanding adoption of these therapeutics. Innovations such as phage display, hybridoma technology, and computational approaches have streamlined the development process, enabling the rapid identification and optimization of antibody candidates. This acceleration in drug development timelines aligns with the growing demand for efficient and effective therapeutic solutions. Antibody therapeutics play a pivotal role in the field of oncology. Monoclonal antibodies (mAbs) are designed to specifically target and bind to cancer cells or proteins associated with cancer growth. These antibodies can be tailored to inhibit critical signaling pathways for cancer cell survival, mark cancer cells for immune system destruction, or deliver cytotoxic agents directly to cancer cells. Examples include Rituximab, Trastuzumab, and Pembrolizumab, which have demonstrated efficacy in treating various cancers.

Rare diseases are incredibly diverse, encompassing various conditions that vary in their symptoms, underlying causes, and clinical manifestations in the US. Advances in medical research and diagnostic capabilities have led to the identification of new rare diseases in the US. The expansion of rare diseases has led to increased clinical trial activity focused on developing and testing antibody therapeutics in the US. Ongoing biotechnology and antibody engineering advancements have expanded the capabilities of developing targeted therapeutics in the US. As per a report by the US Food & Drug Administration updated in 2022, in the US, more than 30 million people suffer from more than 7,000 rare diseases. Due to the above-mentioned factors, the antibody therapeutics market will grow significantly in this region.

The US market dominated the North America Antibody Therapeutics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $165,924.2 million by 2030. The Canada market is experiencing a CAGR of 16.3% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 15.2% during (2023 - 2030).

Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Others. Based on Format, the market is segmented into, Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody, Antibody fragment & Others. Based on Source, the market is segmented into Human, Humanized, and Chimeric. Based on End User, the market is segmented into Hospitals, Long-term care facilities, and Others. Based on Disease Areas, the market is segmented into Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology, Oncology, Infectious Diseases, Immunology, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, AbbVie, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Merck KGaA, Bristol Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Novartis AG, Biogen, Inc. and Amgen, Inc.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration
  • Intravenous
  • Subcutaneous
  • Others
By Format
  • Monoclonal Antibody
  • Polyclonal Antibody Therapy
  • Bispecific Antibody
  • Antibody fragment & Others
By Source
  • Human
  • Humanized
  • Chimeric
By End User
  • Hospitals
  • Long-term care facilities
  • Other
By Disease Areas
  • Autoimmune & Inflammatory Diseases
  • Neurology
  • Osteology
  • Hematology
  • Oncology
  • Infectious Diseases
  • Immunology
  • Others
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America
Companies Profiled
  • F. Hoffmann-La Roche Ltd
  • AbbVie, Inc.
  • Johnson & Johnson (Johnson & Johnson Services, Inc.)
  • Merck KGaA
  • Bristol Myers Squibb Company
  • AstraZeneca PLC
  • Sanofi S.A.
  • Novartis AG
  • Biogen, Inc.
  • Amgen, Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Antibody Therapeutics Market, by Route of Administration
1.4.2 North America Antibody Therapeutics Market, by Format
1.4.3 North America Antibody Therapeutics Market, by Source
1.4.4 North America Antibody Therapeutics Market, by End User
1.4.5 North America Antibody Therapeutics Market, by Disease Areas
1.4.6 North America Antibody Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Antibody Therapeutics market.
Chapter 5. North America Antibody Therapeutics Market by Route of Administration
5.1 North America Intravenous Market by Country
5.2 North America Subcutaneous Market by Country
5.3 North America Others Market by Country
Chapter 6. North America Antibody Therapeutics Market by Format
6.1 North America Monoclonal Antibody Market by Country
6.2 North America Polyclonal Antibody Therapy Market by Country
6.3 North America Bispecific Antibody Market by Country
6.4 North America Antibody fragment & Others Market by Country
Chapter 7. North America Antibody Therapeutics Market by Source
7.1 North America Human Market by Country
7.2 North America Humanized Market by Country
7.3 North America Chimeric Market by Country
7.4 North America Others Market by Country
Chapter 8. North America Antibody Therapeutics Market by End User
8.1 North America Hospitals Market by Country
8.2 North America Long-term care facilities Market by Country
8.3 North America Others Market by Country
Chapter 9. North America Antibody Therapeutics Market by Disease Areas
9.1 North America Autoimmune & Inflammatory Diseases Market by Country
9.2 North America Neurology Market by Country
9.3 North America Osteology Market by Country
9.4 North America Hematology Market by Country
9.5 North America Oncology Market by Country
9.6 North America Infectious Diseases Market by Country
9.7 North America Immunology Market by Country
9.8 North America Others Market by Country
Chapter 10. North America Antibody Therapeutics Market by Country
10.1 US Antibody Therapeutics Market
10.1.1 US Antibody Therapeutics Market by Route of Administration
10.1.2 US Antibody Therapeutics Market by Format
10.1.3 US Antibody Therapeutics Market by Source
10.1.4 US Antibody Therapeutics Market by End User
10.1.5 US Antibody Therapeutics Market by Disease Areas
10.2 Canada Antibody Therapeutics Market
10.2.1 Canada Antibody Therapeutics Market by Route of Administration
10.2.2 Canada Antibody Therapeutics Market by Format
10.2.3 Canada Antibody Therapeutics Market by Source
10.2.4 Canada Antibody Therapeutics Market by End User
10.2.5 Canada Antibody Therapeutics Market by Disease Areas
10.3 Mexico Antibody Therapeutics Market
10.3.1 Mexico Antibody Therapeutics Market by Route of Administration
10.3.2 Mexico Antibody Therapeutics Market by Format
10.3.3 Mexico Antibody Therapeutics Market by Source
10.3.4 Mexico Antibody Therapeutics Market by End User
10.3.5 Mexico Antibody Therapeutics Market by Disease Areas
10.4 Rest of North America Antibody Therapeutics Market
10.4.1 Rest of North America Antibody Therapeutics Market by Route of Administration
10.4.2 Rest of North America Antibody Therapeutics Market by Format
10.4.3 Rest of North America Antibody Therapeutics Market by Source
10.4.4 Rest of North America Antibody Therapeutics Market by End User
10.4.5 Rest of North America Antibody Therapeutics Market by Disease Areas
Chapter 11. Company Profiles
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 Company Overview
11.1.2 Financial Analysis
11.1.3 Segmental and Regional Analysis
11.1.4 Research & Development Expense
11.1.5 Recent strategies and developments:
11.1.5.1 Partnerships, Collaborations, and Agreements:
11.1.5.2 Product Launches and Product Expansions:
11.1.6 SWOT Analysis
11.2 AbbVie, Inc.
11.2.1 Company Overview
11.2.2 Financial Analysis
11.2.3 Regional Analysis
11.2.4 Research & Development Expense
11.2.5 Recent strategies and developments:
11.2.5.1 Partnerships, Collaborations, and Agreements:
11.2.5.2 Acquisition and Mergers:
11.2.6 SWOT Analysis
11.3 Johnson & Johnson (Johnson & Johnson Services, Inc.)
11.3.1 Company Overview
11.3.2 Financial Analysis
11.3.3 Segmental &Regional Analysis
11.3.4 Research & Development Expenses
11.3.5 Recent strategies and developments:
11.3.5.1 Partnerships, Collaborations, and Agreements:
11.3.6 SWOT Analysis
11.4 Merck KGaA
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Segmental and Regional Analysis
11.4.4 Research & Development Expense
11.4.5 Recent strategies and developments:
11.4.5.1 Partnerships, Collaborations, and Agreements:
11.4.6 SWOT Analysis
11.5 Bristol Myers Squibb Company
11.5.1 Company Overview
11.5.2 Financial Analysis
11.5.3 Regional Analysis
11.5.4 Research & Development Expenses
11.5.5 Recent strategies and developments:
11.5.5.1 Acquisition and Mergers:
11.5.6 SWOT Analysis
11.6 AstraZeneca PLC
11.6.1 Company Overview
11.6.2 Financial Analysis
11.6.3 Regional Analysis
11.6.4 Research & Development Expenses
11.6.5 SWOT Analysis
11.7 Sanofi S.A.
11.7.1 Company Overview
11.7.2 Financial Analysis
11.7.3 Segmental and Regional Analysis
11.7.4 Research & Development Expense
11.7.5 SWOT Analysis
11.8 Novartis AG
11.8.1 Company Overview
11.8.2 Financial Analysis
11.8.3 Segmental and Regional Analysis
11.8.4 Research & Development Expense
11.8.5 SWOT Analysis
11.9 Biogen, Inc.
11.9.1 Company Overview
11.9.2 Financial Analysis
11.9.3 Regional Analysis
11.9.4 Research & Development Expense
11.9.5 SWOT Analysis
11.10. Amgen, Inc.
11.10.1 Company Overview
11.10.2 Financial Analysis
11.10.3 Regional Analysis
11.10.4 Research & Development Expenses
11.10.5 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings